REVIEW OF INTERNATIONAL HTA ACTIVITIES ON MEDICAL DEVICES

WORK PACKAGE 1 – DELIVERABLE D 1.2

Dissemination Level: Public

Lead Beneficiary: UEXE
Rod Taylor
Oriana Ciani
Britni Wilcher

Sub-Beneficiaries: HCHE, IER
Maximilian Hatz
Valentina Rupel
Renata Slabe-Erker
Yauheniya Varabyova

December 2013
Version 1
About MedtecHTA

The MedtecHTA project (Methods for Health Technology Assessment of Medical Devices: a European Perspective) aims at improving the existing methodological framework within the paradigm of Health Technology Assessment (HTA) for the assessment of medical devices, and to develop this framework into a tool that provides structured, evidence-based input into health policies. The research activities are conducted by a consortium of six European Universities and one Scientific Association. The project is funded under the European Union’s 7th Framework Programme as Small or Medium-Scale Focused Research Project (2013-2015).

About the Authors

Rod Taylor is WP1 lead based at the Institute of Health Research, University of Exeter Medical School

Oriana Ciani is a contracted researcher on MedtecHTA WP1 and PhD candidate based at the Institute of Health Research, University of Exeter Medical School.

Britni Wilcher is a contracted researcher on MedtecHTA WP1 and PhD candidate based at the Institute of Health Research, University of Exeter Medical School.

The research leading to these results has received funding from the European Community’s Seventh Framework Programme under grant agreement HEALTH-F3-2012-305694 (Project MEDTECHTA).
Acknowledgements

The authors would in particular like to thank Hamburg Center for Economics and the Institute for Economic Research in Slovenia for providing invaluable support with the web-based survey and agency interview process. In addition, we would like to acknowledge other members of the MedtecHTA consortium who commented on the protocol for this project. Finally, we are grateful for the participation and contributions made by those listed below representing government and non-government HTA agencies:

Agency for Healthcare Research and Quality (Washington DC, USA)
Elise Berliner, Ph.D.
Director, Technology Assessment Program Center for Outcomes and Evidence

Blue Cross Blue Shield Association (Chicago & Washington DC, USA)
Naomis Aronson, Ph.D.
Director, Blue Cross and Blue Shield Association Technology Evaluation Center and Evidence-based Practice Center

Canadian Agency for Drugs and Technologies in Health (Ottawa, Ontario - Canada)
Tammy Clifford, Ph.D.
Vice President of Strategic Initiatives/Chief Scientist
Michelle Mujoomdar, Ph.D.
Assistant Chief Scientist
Stirling Bryan, Ph.D.
Chair, Health Technology Expert Review Panel

Center for Drug Evaluation (Taipei, Taiwan)
Jasmine R.F. Pwu, Ph.D.
Executive Director, Division of HTA

Centro Nacional de Excelencia Tecnológica en Salud (Mexico City, Mexico)
Veronica Gallegos Rivero

Charlotte Maxeke Research Consortium (Parktown, South Africa)
Jani Mueller

Coordenação Geral de Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia (São Paulo, Brazil)
Isadora Fernandez Patterson
Lawyer and Specialist

Evidence Development and Standards, Health Quality Ontario (Toronto, Ontario - Canada)
Les Levin, M.D.
Vice President, Evidence Development and Standards

Health Intervention and Technology Assessment Program (Nonthaburi, Thailand)
Sripen Tantivess, Ph.D.
Senior Researcher

Health Services Assessment Collaboration (Christchurch, New Zealand)
Ray Kirk
Director

Institute for Clinical & Economic Review (Boston, USA)
Dan Ollendorf
Chief Review Officer
Steve Pearson, M.D.
President, Institute for Clinical and Economic Review

Institute for Clinical Effectiveness and Health Policy (Buenos Aires, Argentina)
Federico Augustovski, M.D.
Director, Health Economic Evaluations and Technology Assessment
Adres Pinchon Rivere, M.D., Ph.D.
Executive Director

Institute of Health Economics (Edmonton, Alberta - Canada)
Christa Harstall
Director of Health Technology Assessment

Institut national d'excellence en santé et en services (Québec, Québec - Canada)
Reiner Banken, M.D.
Associate general director of External Affairs, Partnerships and Networks

Health Technology Assessment Section, Ministry of Health Malaysia (Putrajaya, Malaysia)
Rugayah Bakri, M.D.
Director, Health Technology Assessment Section
Izzuna Ghazali, M.D.
Senior Principal Assistant Director

The Medical Services Advisory Committee (Canberra, Australia)

National Evidence-based Healthcare Collaboration Agency (Seoul, Korea)
Professor Om, Yong Jin
Former Chairman, NECA
Jeonghoon Ahn, Ph.D.
Executive Director, Office of Health Services Research (OHSR)
Lee, Moo-Yeol, M.D., Ph.D.
Executive Director of Center for New Health Technology Assessment

New Zealand National Health Committee (Wellington, New Zealand)
Erin Holmes
Senior Advisor
Susan Martindale
Principal Advisor, Medsafe

National Healthcare Group (Singapore)
Dr. Heng Bee Hoon

Norwegian Knowledge Center for the Health Services (Oslo, Norway)
Inger Norderhaug
Research Director

Pharmacoeconomic Unit - Central Administration for Pharmaceutical Affairs (Cairo, Egypt)
Gihan El-sisi
Head of Pharmacoeconomic Unit, Central Administration for Pharmaceutical Affairs

Pharmaceutical Management Agency of New Zealand Management Team (Wellington, New Zealand)

University of Calgary (Calgary, Alberta - Canada)
Fiona Clement, Ph.D.
Director, Institute for Public Health
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AHRQ</td>
<td>Agency for Healthcare Research and Quality (Washington DC, USA)</td>
</tr>
<tr>
<td>AHTA</td>
<td>Adelaide Health Technology Assessment (Adelaide, Australia)</td>
</tr>
<tr>
<td>ASERNIP-S</td>
<td>Australian Safety and Efficacy Register of New Interventional Procedures – Surgical (Adelaide, Australia)</td>
</tr>
<tr>
<td>BCBSA</td>
<td>Blue Cross Blue Shield Association (Chicago &amp; Washington DC, USA)</td>
</tr>
<tr>
<td>BSCF</td>
<td>Blue Shield of California Foundation (San Francisco, CA)</td>
</tr>
<tr>
<td>CADTH</td>
<td>Canadian Agency for Drugs and Technologies in Health (Ottawa, Ontario)</td>
</tr>
<tr>
<td>CDE</td>
<td>Center for Drug Evaluation (Taipei, Taiwan)</td>
</tr>
<tr>
<td>CENETEC</td>
<td>Centro Nacional de Excelencia Tecnológica en Salud (Mexico City, Mexico)</td>
</tr>
<tr>
<td>CMerRC</td>
<td>Charlotte Maxeke Research Consortium (Parktown, South Africa)</td>
</tr>
<tr>
<td>DECIT</td>
<td>Coordenação Geral de Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia (São Paulo, Brazil)</td>
</tr>
<tr>
<td>ECRI</td>
<td>Emergency Care Research Institute (Plymouth Meeting, USA)</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>EUnetHTA</td>
<td>European Network for Health Technology Assessment</td>
</tr>
<tr>
<td>EXCITE</td>
<td>MaRS Excellence in Clinical Technology Evaluation</td>
</tr>
<tr>
<td>HITAP</td>
<td>Health Intervention and Technology Assessment Program (Nonthaburi, Thailand)</td>
</tr>
<tr>
<td>HQO</td>
<td>Evidence Development and Standards, Health Quality Ontario (Toronto, Ontario - Canada)</td>
</tr>
<tr>
<td>HSAC</td>
<td>Health Services Assessment Collaboration (Christchurch, New Zealand)</td>
</tr>
<tr>
<td>HTA</td>
<td>Health Technology Assessment</td>
</tr>
<tr>
<td>HTAi</td>
<td>Health Technology Assessment International</td>
</tr>
<tr>
<td>ICER</td>
<td>Institute for Clinical &amp; Economic Review (Boston, USA)</td>
</tr>
<tr>
<td>IECS</td>
<td>Institute for Clinical Effectiveness and Health Policy (Buenos Aires, Argentina)</td>
</tr>
<tr>
<td>IETS</td>
<td>Instituto de Evaluación Tecnológica en Salud (Bogotá, Colombia)</td>
</tr>
<tr>
<td>IHE</td>
<td>Institute of Health Economics (Edmonton, Alberta - Canada)</td>
</tr>
<tr>
<td>INAHTA</td>
<td>International Network of Agencies for Health Technology Assessment</td>
</tr>
<tr>
<td>INESS</td>
<td>Institut national d’excellence en santé et en services (Québec, Québec - Canada)</td>
</tr>
<tr>
<td>MaHTAS</td>
<td>Health Technology Assessment Section, Ministry of Health Malaysia (Putrajaya, Malaysia)</td>
</tr>
<tr>
<td>MD</td>
<td>Medical Device</td>
</tr>
</tbody>
</table>
MedtecHTA  |  Methods for Health Technology Assessment of Medical Devices
MoH, Singapore  |  Ministry of Health, Singapore (Singapore)
MSAC  |  Medical Services Advisory Committee (Canberra, Australia)
MSP  |  Ministry of Public Health of Uruguay (Montevideo, Uruguay)
MTU-SFOPH  |  Medical Technology Unit - Swiss Federal Office of Public Health (Berne, Switzerland)
NECA  |  National Evidence-based healthcare Collaboration Agency (Seoul, Korea)
NHC  |  New Zealand National Health Committee (Wellington, New Zealand)
NHG  |  National Healthcare Group (Singapore)
NHMR CTC  |  NHMRC Clinical Trials Centre (Camperdown, Australia)
NOKC  |  Norwegian Knowledge Center for the Health Services (Oslo, Norway)
OHTAC  |  Ontario Health Technology Advisory Committee (Toronto, Ontario - Canada)
PATH  |  Programs for Assessment of Technology in Health Research Institute (Hamilton, Ontario - Canada)
PE Unit  |  Pharmacoeconomic Unit - Central Administration for Pharmaceutical Affairs (Cairo, Egypt)
PLAC  |  Prostheses List Advisory Committee (Canberra, Australia)
RCHD-CS  |  Ministry of Public Health of the Republic of Kazakhstan, Republican Centre for Health Development, Centre of Standardization, HTA department (Astana City, Kazakhstan)
SHS  |  Singapore Health Services (Singapore)
SME  |  Subject Matter Expert
SUS  |  Brazilian Public Health System
UCEETS  |  The National Coordination Unit of Health Technology Assessment and Implementation (Buenos Aires, Argentina)
UoC  |  University of Calgary (Calgary, Alberta)
WHO  |  World Health Organization
Executive Summary

Background

Policymakers increasingly rely on Health Technology Assessment (HTA) to make decisions about health technology coverage and reimbursement. While there have been a number of previous surveys of international HTA agency practice few have specifically assessed medical device evaluation.

Objective

The overarching objective of this study was to review and compare current HTA activities for medical devices across non-European HTA agencies with particular reference to their structure, processes, and methods.

Methods

The identification of agencies for inclusion in this study was based on their membership (as of February 2013) in: Heath Technology Assessment International (HTAi), European network for Health Technology Assessment (EUnetHTA), International Network of Agencies for Health Technology Assessment (INAHTA) and World Health Organization (WHO) Collaborating Centers for HTA.

Included agencies’ HTA procedures for medical devices were evaluated from three organisational perspectives:

1) Structure: How is the agency organised?
2) Process: What are the agency’s HTA standard operating procedures?
3) Methods: What scientific methodologies underpin the assessment process?

Data collection consisted of two phases: web-based survey of all included agencies and semi-structured interviews with those agencies identified to have medical device specific procedures.

Key Findings

Our final sample included 36 HTA agencies across 19 non-EU countries. In accordance with good practice principle #3 for HTA agencies proposed by Drummond and colleagues (i.e., ‘HTA should include all relevant technologies’), the majority (36/41, 88%) of agencies identified included the assessment of medical devices alongside drugs, and other medical technologies, such as diagnostic tests. In addition, 27 out of the 36 (75%) agencies evaluating medical devices have also developed approaches specific to the assessment and appraisal of medical devices. Seventy-eight (21/27) and sixty-seven percent (18/27) of agencies have developed specific structural and procedural processes respectively for the evaluation of medical devices. Only one agency, the Department of Science and Technology in Brazil, reported that they developed specific methodological guidance for the HTA medical devices.

Interviews with agencies confirmed a number of commonly cited challenges in the HTA of medical devices, including relatively poor quality of evidence for medical
devices, problems with generalising the medical device evidence obtained in a specific setting to another, the ‘learning curve’ (i.e., the clinical outcomes of medical devices depend on training and experience of operator or the clinical setting in which the device is being used), and difficulty scoping the decision problem for HTA of medical devices.

The vast majority of agencies appeared to apply the same methodological approach to assessment of medical devices as non-devices. However, we did identify some innovative approaches to evidence generation and HTA assessment for medical devices such as the MaRS Excellence in Clinical Technology Evaluation (EXCITE) programme recently established in Ontario, Canada. This programme seeks to assist medical device manufacturers with the design of studies and collection of evidence that would allow them to fulfill the requirements for both regulators and HTA decision-making authorities.

Policy Implications

In contrast to regulatory requirements that are fairly consistent across international settings, HTA procedures for medical devices appear to vary widely across countries.

It is well accepted that medical devices differ from drugs and other health technologies in a number of specific ways (e.g., learning curve, incremental technology innovation). However, we found little evidence of differentiation in the methods used by HTA agencies to assess devices compared to non-device technologies. Our findings therefore raise the question of whether the differences are such to demand that HTA procedures (i.e., structure, processes and methods) be tailored specifically to meet the needs of medical devices.